ZA200708601B - 39-desmethoxy derivatives of rapamycin - Google Patents

39-desmethoxy derivatives of rapamycin

Info

Publication number
ZA200708601B
ZA200708601B ZA200708601A ZA200708601A ZA200708601B ZA 200708601 B ZA200708601 B ZA 200708601B ZA 200708601 A ZA200708601 A ZA 200708601A ZA 200708601 A ZA200708601 A ZA 200708601A ZA 200708601 B ZA200708601 B ZA 200708601B
Authority
ZA
South Africa
Prior art keywords
rapamycin
desmethoxy derivatives
desmethoxy
derivatives
Prior art date
Application number
ZA200708601A
Other languages
English (en)
Inventor
Beckmann Christoph Hendrik
Moss Steven James
Sheridan Rose Mary
Zhang Mingqiang
Wilkinson Barrie
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of ZA200708601B publication Critical patent/ZA200708601B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200708601A 2005-03-11 2006-03-10 39-desmethoxy derivatives of rapamycin ZA200708601B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504994.5A GB0504994D0 (en) 2005-03-11 2005-03-11 Novel compounds

Publications (1)

Publication Number Publication Date
ZA200708601B true ZA200708601B (en) 2009-02-25

Family

ID=34508873

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708601A ZA200708601B (en) 2005-03-11 2006-03-10 39-desmethoxy derivatives of rapamycin

Country Status (24)

Country Link
US (2) US7648996B2 (ko)
EP (1) EP1856129B8 (ko)
JP (1) JP5422788B2 (ko)
KR (1) KR20070113282A (ko)
CN (2) CN101175760B (ko)
AU (1) AU2006221786B2 (ko)
BR (1) BRPI0607441A2 (ko)
CA (1) CA2600640C (ko)
CR (1) CR9434A (ko)
DK (1) DK1856129T3 (ko)
ES (1) ES2527530T3 (ko)
GB (1) GB0504994D0 (ko)
HR (1) HRP20150012T1 (ko)
IL (1) IL185688A0 (ko)
MX (1) MX2007011131A (ko)
NI (1) NI200700230A (ko)
NO (1) NO20074594L (ko)
NZ (1) NZ561607A (ko)
PL (1) PL1856129T3 (ko)
PT (1) PT1856129E (ko)
RS (1) RS53778B1 (ko)
RU (1) RU2391346C2 (ko)
WO (1) WO2006095185A1 (ko)
ZA (1) ZA200708601B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862538B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
EP1896018A2 (en) * 2005-03-11 2008-03-12 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
CN101836980A (zh) * 2005-03-11 2010-09-22 比奥蒂卡科技有限公司 39-去甲氧基雷帕霉素及其类似物的医药用途
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
WO2007056118A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CN102579467A (zh) 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
GB0609963D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CA2678415A1 (en) * 2007-04-05 2008-10-16 Wyeth Wortmannin-rapamycin conjugate and uses thereof
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
EP3000467B1 (en) 2009-04-06 2023-03-01 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
US8754207B2 (en) 2009-09-25 2014-06-17 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
WO2011053938A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
CN106153755B (zh) * 2015-04-24 2020-02-14 山东新时代药业有限公司 2-(叔丁基二甲基硅烷基氧基)乙醇的分析检测方法
AU2016315653A1 (en) * 2015-08-28 2018-03-15 Buck Institute For Research On Aging Rapamycin analogs showing improved mTORC1 specificity
JP2020507632A (ja) * 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
AR112834A1 (es) * 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
EP3880266A1 (en) 2018-11-14 2021-09-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
JP3140228B2 (ja) 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
US5995457A (en) * 1993-12-22 1999-11-30 Jamail; Randall H. Method of masking data on digital video disks (DVD)
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
ATE222502T1 (de) 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
AU777997B2 (en) 1999-07-09 2004-11-11 Oregon Health And Science University Compositions and methods for promoting nerve regeneration
DK1278758T3 (da) 2000-04-27 2012-01-23 Univ Arizona Combretastatin A-1-phosphat- og combretastatin B-1-phosphat-prodrugs
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
ES2728739T3 (es) * 2001-02-19 2019-10-28 Novartis Pharma Ag Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
EP2407473A3 (en) * 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
ES2296063T3 (es) * 2002-07-16 2008-04-16 Biotica Technology Limited Produccion de poliquetidos y otros productos naturales.
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
EP1896018A2 (en) 2005-03-11 2008-03-12 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound

Also Published As

Publication number Publication date
EP1856129B8 (en) 2015-06-03
GB0504994D0 (en) 2005-04-20
MX2007011131A (es) 2007-11-13
WO2006095185A1 (en) 2006-09-14
US8008318B2 (en) 2011-08-30
BRPI0607441A2 (pt) 2010-04-06
RU2007137668A (ru) 2009-04-20
DK1856129T3 (en) 2015-01-05
AU2006221786B2 (en) 2012-02-16
RS53778B1 (en) 2015-06-30
PL1856129T3 (pl) 2015-08-31
ES2527530T3 (es) 2015-01-26
HRP20150012T1 (en) 2015-03-27
CN101175760B (zh) 2014-08-13
KR20070113282A (ko) 2007-11-28
NO20074594L (no) 2007-10-15
CA2600640C (en) 2015-10-27
CN104211715A (zh) 2014-12-17
RU2391346C2 (ru) 2010-06-10
NZ561607A (en) 2011-01-28
US20080188511A1 (en) 2008-08-07
EP1856129B1 (en) 2014-10-15
JP5422788B2 (ja) 2014-02-19
PT1856129E (pt) 2015-01-16
CN101175760A (zh) 2008-05-07
US7648996B2 (en) 2010-01-19
US20100081682A1 (en) 2010-04-01
CR9434A (es) 2008-02-22
IL185688A0 (en) 2008-01-06
CA2600640A1 (en) 2006-09-14
NI200700230A (es) 2008-05-13
EP1856129A1 (en) 2007-11-21
JP2008532991A (ja) 2008-08-21
AU2006221786A1 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
HRP20150012T1 (en) 39-desmethoxy derivatives of rapamycin
SI1802579T1 (sl) Derivati 3-arilaminopiridina
ZA200707523B (en) Purification of rapamycin
HUS2000022I1 (hu) Tiglien-3-on származékok
EP1878727A4 (en) 2-AMINOQUINAZOLINE DERIVATIVES
ZA200805411B (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
ZA200707358B (en) 1-benzylindole-2-carboxamide derivatives
PL1954674T3 (pl) Nowe pochodne N-fenetylokarboksyamidu
GB2424881B (en) Halophenyl derivatives of bisalkylfluorene
ZA200802088B (en) 4-Phenyl-6-substitued-pyrimidine-2-carbonitrile derivatives
ZA200802421B (en) 1-Acyldihydropyrazol derivatives
ZA200804257B (en) Azaindole-2-carboxamide derivatives
AP2007004282A0 (en) Derivatives of A 1-phenyltriazole as antiparasiticagents
IL192235A0 (en) Aryl-isoxazol-4-yl-imidazole derivatives
HK1122797A1 (en) Derivatives of pyrido
GB0622472D0 (en) Novel heterocyclic derivatives
IL191138A0 (en) Pyrazoloisoquinoline derivatives
ZA200802775B (en) 9-aminocarbonylsubstituted derivatives of glycylcyclines
GB0511410D0 (en) Benzotrizepinone derivatives
TWI340746B (en) Naphthyridin derivatives
IL186143A0 (en) Pro-drugs of n-thiazol-2yl-benzamide derivatives
ZA200706577B (en) Dihydroimidazothiazole derivatives
ZA200707966B (en) Pro-drugs of n-thiazol-2yl-benzamide derivatives
HUP0500461A3 (en) Pyperazine derivatives of alkyl-oxindoles
PL381715A1 (pl) Nowe pochodne piperazynowe dialkilooksindoli